Browse Category

NASDAQ:SOBR News 25 December 2025

SOBR Safe (SOBR) Stock After the Bell on Dec. 24, 2025: 82% Surge, Then a $2M Private Placement — What to Know Before Markets Reopen

SOBR Safe (SOBR) Stock After the Bell on Dec. 24, 2025: 82% Surge, Then a $2M Private Placement — What to Know Before Markets Reopen

SOBR Safe, Inc. (NASDAQ: SOBR) ended Christmas Eve with one of the most eye‑catching microcap moves on the tape — and then followed it with a financing headline after the close. On a holiday‑shortened U.S. trading day (the market closed early at 1:00 p.m. ET), SOBR stock surged sharply, with RTTNews reporting a gain of 82.30% to $2.37 by the end of the regular session. RTTNews+1In the after‑hours session, the stock gave back part of that move: Public.com showed SOBR around $2.03 at 5:00 p.m. ET, down about 14% from the regular close, with after‑hours trading ranging roughly $1.95–$2.07. Public+1
25 December 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop